drugset / Trial / NCT02219412

Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy

NCT02219412 ↗

Phase 4 Completed 70 enrolled Yong Huo
RandomizedParallel-groupOpen-labelTreatment

Summary

This study was a feasibility trial that was designed to provide preliminary observations and generate hypotheses for future studies. The aim of the study is to estimate the difference of arachidonic acid induced platelet aggregation rate between ticagrelor mono-therapy and aspirin/ticagrelor dual-therapy after 14 days of treatment in patients with stable coronary artery disease. The potential hypothesis is that the arachidonic acid (AA) induced platelet aggregation rate after 2 weeks of ticagrelor mono-therapy is comparable to that of aspirin/ticagrelor dual-therapy.

Timeline

Start
2014-08
Primary completion
2015-06
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg —
Subject Ticagrelor Small molecule 90 mg —